Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test
Shots:
- TScan signs exclusive research and option to license agreement with Qiagen to develop T cell-based laboratory tests for detecting prior exposure to the SARS-CoV-2
- Qiagen gets an option to license the rights and IP for several of TScan discovered immunodominant T cell targets- associated sequences and relevant data for the development and commercialization of IVD tests. In advance of exercising its option- Qiagen has the right to evaluate TScan’s discoveries
- The targeted immunodominant were identified through the T-Scan TCR/Target discovery platform enabling the mapping of the specific epitopes in SARS-CoV-2
Ref: Businesswire | Image: TrialSite News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com